Isolated rat stomach ECL cells generate prostaglandin E(2) in response to interleukin-1 beta, tumor necrosis factor-alpha and bradykinin

Eur J Pharmacol. 2001 Mar 30;416(3):255-63. doi: 10.1016/s0014-2999(01)00881-0.

Abstract

The ECL cells control parietal cells by releasing histamine in their immediate vicinity. Gastrin and pituitary adenylate cyclase-activating peptide (PACAP) stimulate histamine secretion from isolated ECL cells, while somatostatin and galanin inhibit stimulated secretion. Prostaglandin E2 and related prostaglandins likewise suppress ECL-cell histamine secretion. Conceivably, that is how they inhibit acid secretion. In the present study, we examined if prostaglandin E2 can be generated by isolated ECL cells. Rat stomach ECL cells were purified (>90% purity) by counterflow elutriation and gradient centrifugation and cultured for 48 h. ECL cell stimulants (gastrin and PACAP) and inflammatory agents (interleukin-1 beta, tumor necrosis factor-alpha and bradykinin) were tested for their ability to induce prostaglandin E2 accumulation (24-h incubation), measured by radioimmunoassay. Gastrin and PACAP did not affect prostaglandin E2 accumulation but interleukin-1 beta (300 pg/ml), tumor necrosis factor-alpha (10 ng/ml) and bradykinin (1 microM) induced a 2- to 3-fold increase in the amount of prostaglandin E2 accumulated. While the combination of interleukin-1 beta and bradykinin induced a 9-fold increase, the combination interleukin-1 beta+tumor necrosis factor-alpha and bradykinin + tumor necrosis factor-alpha induced additive effects only. The combination of interleukin-1 beta + tumor necrosis factor-alpha + bradykinin did not induce a greater effect than interleukin-1 beta + bradykinin. The effect of interleukin-1 beta + bradykinin was abolished by adding 10 nM hydrocortisone (suppressing phospholipase A2 and cyclooxygenase) or 1 microM indomethacin (inhibiting cyclooxygenase). Incubating ECL cells in the presence of interleukin-1 beta+bradykinin for 24 h reduced their ability to secrete histamine in response to gastrin. The inhibitory effect was reversed by 1 microM indomethacin. Also, increasing the concentrations of hydrocortisone in the medium resulted in an enhanced gastrin-stimulated histamine secretion. Hence, the previously described acid-inhibiting effect of inflammatory agents may be explained by inhibition of ECL-cell histamine mobilization, consequent to enhanced formation of prostaglandin E2 by cells in the oxyntic mucosa, including the ECL cells themselves.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Bradykinin / pharmacology*
  • Cells, Cultured
  • Dinoprostone / metabolism*
  • Dose-Response Relationship, Drug
  • Enterochromaffin-like Cells / drug effects
  • Enterochromaffin-like Cells / metabolism*
  • Gastrins / pharmacology
  • Histamine Release / drug effects
  • Humans
  • Hydrocortisone / pharmacology
  • Indomethacin / pharmacology
  • Interleukin-1 / pharmacology*
  • Male
  • Models, Biological
  • Neuropeptides / pharmacology
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Rats
  • Rats, Sprague-Dawley
  • Stomach / cytology
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Vasodilator Agents / pharmacology

Substances

  • ADCYAP1 protein, human
  • Adcyap1 protein, rat
  • Anti-Inflammatory Agents
  • Gastrins
  • Interleukin-1
  • Neuropeptides
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Tumor Necrosis Factor-alpha
  • Vasodilator Agents
  • gastrin 17
  • Dinoprostone
  • Bradykinin
  • Hydrocortisone
  • Indomethacin